EUVIMEDEUVIMED entdecken
Crossref

Early outcomes from a new multidisciplinary cardiometabolic clinic: real‐world experience in lowering low‐density lipoprotein cholesterol

Ying Yi Wendy Yap iD, Nick S R Lan iD, Girish Dwivedi, Bu B Yeap, P Gerry Fegan iD, Krishnamurthy Chikkaveerappa

Internal Medicine Journal · 2026-03 · 56 (3) · 475-480

DOI: 10.1111/imj.70334 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Internal Medicine Journal, online erschienen am 24.02.2026. Verfasst von Ying Yi Wendy Yap und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Diabetes, Fiona Stanley Hospital, Perth, Western Australia, Australia. Hauptthemen laut MEDLINE: Cholesterol, LDL, Anticholesteremic Agents, Cardiovascular Diseases, Hyperlipoproteinemia Type II. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 18 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study presents real‐world data on low‐density lipoprotein cholesterol (LDL‐C) management in the first 200 patients seen at a new multidisciplinary cardiometabolic clinic from January 2023, with follow‐up until April 2024. The cohort had a mean ± standard deviation age of 52 ± 14 years, 51% were male, 69 (35%) had familial hypercholesterolaemia and 66 (33%) had cardiovascular disease. Lipid‐lowering therapies were escalated in 120 (60%) patients. Median low‐density lipoprotein cholesterol level decreased with initiation of evolocumab (69%), inclisiran (56%), statin (45%) and ezetimibe (21%). In patients with a history of statin intolerance, 19 (43%) re‐initiated or increased statin dose.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cholesterol, LDLAnticholesteremic AgentsCardiovascular DiseasesHyperlipoproteinemia Type IIHumansMaleMiddle AgedFemaleHydroxymethylglutaryl-CoA Reductase InhibitorsEzetimibeTreatment OutcomeAntibodies, Monoclonal, HumanizedAdultAged

Stichwörter der Autor:innen

LDL cholesterolcardiometabolicdyslipidaemiamultidisciplinary

Substanzen

Cholesterol, LDLAnticholesteremic AgentsHydroxymethylglutaryl-CoA Reductase InhibitorsEzetimibeevolocumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Endocrinology and Diabetes, Fiona Stanley Hospital, Perth, Western Australia, Australia.
  • Department of Cardiology, Fiona Stanley Hospital, Perth, Western Australia, Australia.
  • Medical School, University of Western Australia, Perth, Western Australia, Australia.
  • Harry Perkins Institute of Medical Research, Perth, Western Australia, Australia.
  • CardioInnovate Translational Lab Western Australia, Victor Chang Cardiac Research Institute, Sydney, New South Wales, Australia.
  • Medical School, Curtin University, Perth, Western Australia, Australia.

ORCID-Profile: Ying Yi Wendy Yap, Nick S R Lan, P Gerry Fegan

Zitieren

APA

Yap, Y. Y. W., Lan, N. S. R., Dwivedi, G., Yeap, B. B., Fegan, P. G., & Chikkaveerappa, K. (2026). Early outcomes from a new multidisciplinary cardiometabolic clinic: real‐world experience in lowering low‐density lipoprotein cholesterol. Internal Medicine Journal, 56(3), 475-480. https://doi.org/10.1111/imj.70334

Vancouver

Yap YYW, Lan NSR, Dwivedi G, Yeap BB, Fegan PG, Chikkaveerappa K. Early outcomes from a new multidisciplinary cardiometabolic clinic: real‐world experience in lowering low‐density lipoprotein cholesterol. Internal Medicine Journal. 2026;56(3):475-480. doi:10.1111/imj.70334

BibTeX
@article{Yap2026,
  author = {Yap, Ying Yi Wendy and Lan, Nick S R and Dwivedi, Girish and Yeap, Bu B and Fegan, P Gerry and Chikkaveerappa, Krishnamurthy},
  title = {Early outcomes from a new multidisciplinary cardiometabolic clinic: real‐world experience in lowering low‐density lipoprotein cholesterol},
  journal = {Internal Medicine Journal},
  year = {2026},
  volume = {56},
  number = {3},
  pages = {475--480},
  doi = {10.1111/imj.70334}
}
Kostenlos starten →